Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Rewriting the code of life: CRISPR-Cas9 genome editing

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.07.19
Views: 2956

Prof Jennifer Doudna - University of Berkeley, Berkeley, USA

Prof Jennifer Doudna speaks to ecancer at the WIN 2019 Symposium in Paris about the use of genome editing using CRISPR-Cas9 to understand the genetic basis of cancer and to target the immune system.

She explains the basics of this technology and how this may be used in the context of cancer immunotherapy - such as to reprogram T-cells to recognise cancer cells more effectively.

Prof Doudna also discusses the challenges associated with this method, including its delivery into specific tissue types and ethical challenges.

Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation